PROTECT H2H: Emboliner vs. Sentinel Embolic Protection Devices in TAVR

The PROTECT H2H trial, presented at ACC.26, is the first head‑to‑head comparison of two embolic‑protection systems used during transcatheter aortic valve replacement (TAVR). 

In this multicenter, open‑label trial across 20 sites in Brazil, Germany, and the U.S., 522 patients with severe aortic stenosis were randomized to the investigational Emboliner full‑body filter catheter or the U.S. FDA‑approved Sentinel cerebral‑protection system. 

At 30 days, the composite of all‑cause death, stroke, and acute kidney failure occurred in 4.9% of the Emboliner group versus 5.0% of the Sentinel group, with stroke rates of 2% vs. 2.1%—among the lowest reported in any TAVR‑protection trial.

The Emboliner captured three times as many particles larger than 150 microns and nearly twice as many total debris as Sentinel, with successful placement in 96% of cases versus 87% for Sentinel.

Rates of bleeding, thrombosis, and other procedural adverse events were similar between systems. The authors highlight that the Emboliner’s broader full‑body debris capture raises the hypothesis that blocking embolic material to organs beyond the brain—such as the kidneys, gut, and lower extremities—could further improve TAVR outcomes, as long as the platform remains safe and easy to use. 

Given the short 30‑day follow‑up and limited sample size, the trial was underpowered to detect differences in kidney‑failure risk or very rare events, so longer‑term registries will be key to defining the incremental benefit of more extensive embolic‑protection strategies.

---

Checklists for the practicing cardiologist

• Consider embolic‑protection devices (Sentinel or Emboliner‑like platforms) in high‑risk TAVR patients, especially those with prior stroke, atrial fibrillation, or extensive aortic‑calcification, pending full regulatory and guideline adoption.

• For Emboliner‑type systems, weigh the potential benefit of full‑body debris capture against added catheter‑manipulation complexity, procedural time, and cost, particularly in patients with multiple comorbidities.

• For Sentinel‑type systems, continue using them as a cerebral‑centric standard of care when available, ensuring proper positioning in the common carotid and subclavian arteries and confirming wire‑safe snare technique.

• Monitor stroke, acute kidney injury, and major bleeding within 30 days after TAVR, and link these outcomes to registry data to help clarify whether broader embolic‑protection translates into meaningful reductions in non‑cerebral organ injury over time.

• In multidisciplinary TAVR meetings, balance anatomical risk factors (calcified aortic arch, porcelain aorta, peripheral‑vessel disease) and patient‑specific factors (frailty, anticoagulation status, prior embolic events) when deciding which, if any, embolic‑protection strategy to deploy, and remain vigilant for future outcomes‑driven guidance from extended follow‑up and real‑world registries.